Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In Brief

This article was originally published in The Gray Sheet

Executive Summary

D.C. consulting hire: Becker & Associates taps Elaine C. Messa as director, medical device quality systems and compliance. As former director of FDA's Los Angeles field district office, Messa oversaw the largest import operations and medical device workload in the agency, the health care consulting firm says. Messa, who has also chaired CDRH's field committee, left FDA in 1999 to join Quintiles Transnational. At Becker, Messa is charged with expanding the firm's compliance practice, where she will focus on enforcement action responses and international supply-chain risk management

You may also be interested in...

Acquisitions In Brief

Invitrogen deal for Applied Biosystems valued at $6.7 billion: Applera sells its Applied Biosystems research instrument business to biotech research firm Invitrogen for cash and stock worth $6.7 billion, creating "a global leader in biotechnology reagents and systems," the firms announce June 12. Invitrogen will pay $38 per share for Applied Biosystems - a 17% premium over the firm's June 11 closing price. Applera notes that the transaction, expected to close this fall, will have minimal impact on the timing of its previously planned spin-off of its smaller Celera Group diagnostics business, which is scheduled for July (1"The Gray Sheet" May 12, 2008, In Brief)

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts